Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Role of Angiogenesis Inhibitors in Hypertension: Following “Ariadne’s Thread”

The Role of Angiogenesis Inhibitors in Hypertension: Following “Ariadne’s Thread” Arterial hypertension (HT) is one of the most frequently recorded comorbidities among patients under antiangiogenic therapy. Inhibitors of vascular endothelial growth factor and vascular endothelial growth factor receptors are most commonly involved in new onset or exacerbation of pre-existing controlled HT. From the pathophysiology point of view, data support that reduced nitric oxide release and sodium and fluid retention, microvascular rarefaction, elevated vasoconstrictor levels, and globular injury might contribute to HT. The purpose of this review was to present recent evidence regarding the incidence of HT induced by antiangiogenic agents, to analyze the pathophysiological mechanisms, and to summarize current recommendations for the management of elevated blood pressure in this field. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Hypertension Oxford University Press

The Role of Angiogenesis Inhibitors in Hypertension: Following “Ariadne’s Thread”

Download PDF
9 pages

Loading next page...
 
/lp/ou_press/the-role-of-angiogenesis-inhibitors-in-hypertension-following-ariadne-bpGvqrWqEN

References (80)

Publisher
Oxford University Press
Copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
ISSN
0895-7061
eISSN
1941-7225
DOI
10.1093/ajh/hpy087
Publisher site
See Article on Publisher Site

Abstract

Arterial hypertension (HT) is one of the most frequently recorded comorbidities among patients under antiangiogenic therapy. Inhibitors of vascular endothelial growth factor and vascular endothelial growth factor receptors are most commonly involved in new onset or exacerbation of pre-existing controlled HT. From the pathophysiology point of view, data support that reduced nitric oxide release and sodium and fluid retention, microvascular rarefaction, elevated vasoconstrictor levels, and globular injury might contribute to HT. The purpose of this review was to present recent evidence regarding the incidence of HT induced by antiangiogenic agents, to analyze the pathophysiological mechanisms, and to summarize current recommendations for the management of elevated blood pressure in this field.

Journal

American Journal of Hypertension – Oxford University Press

Published: Aug 3, 2018

Keywords: blood pressure; cancer; angiogenesis; chemotherapy; hypertension

There are no references for this article.